BioMarin stock steadies after September 17 close

Published on 09/18/2026 at 16:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioMarin stock ended September 17 at USD 65.08, up 0.54 percent. The 52-week range was USD 49.259 to USD 70.980, with market cap at USD 12.60 billion.

BURL, US10928Q1031, Illustration mit AI erstellt.

BioMarin stock (US10928Q1031) closed at USD 65.08 on September 17, 2026, up 0.54 percent from USD 64.73, with volume at 12.60 million shares and a market capitalization of USD 12.59778 billion.

Trading range stays intact

The share price traded between USD 64.97 and USD 66.21 on September 17, 2026, and the 52-week span reached from USD 49.259 to USD 70.980. That places the stock 7.0 percent below the yearly high and 32.3 percent above the yearly low.

Fundamentals remain recent

For 2026, BioMarin Pharmaceutical Inc. guided revenue growth to 16 percent to 19 percent and non-GAAP diluted earnings per share to USD 4.15 to USD 4.35, according to the companys full-year outlook. In the second quarter of 2026, revenue rose 17 percent year over year to USD 745.3 million, while non-GAAP operating margin reached 40 percent.

BioMarin also reported second-quarter 2026 product revenue of USD 742.6 million and non-GAAP net income of USD 178.1 million, or USD 0.93 per diluted share. The numbers point to a business that is still expanding at a double-digit pace while keeping profitability in view.

What investors watch

For investors, the key issue is whether the 2026 revenue guide of 16 percent to 19 percent can hold after a first-half run that already showed 17 percent growth in Q2 2026. The stock is trading closer to the upper half of its annual band than to the low end.

BioMarin stock near the upper half

BioMarin stock finished September 17, 2026 at USD 65.08 on Nasdaq, with market cap at USD 12.59778 billion and the 52-week high at USD 70.980. The next move will depend on whether the company keeps its 2026 growth and margin targets on track.